FQ
RVMD icon

First Quadrant’s Revolution Medicines RVMD Stock Holding History

First Quadrant’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,700
Closed -$269K – 454
2021
Q4 		$269K Hold
10,700
– – 0.03% 319
2021
Q3 		$294K Buy
10,700
+1,900
+22% +$55.3K 0.03% 298
2021
Q2 		$279K Hold
8,800
– – 0.03% 303
2021
Q1 		$404K Hold
8,800
– – 0.04% 286
2020
Q4 		$348K Hold
8,800
– – 0.03% 297
2020
Q3 		$306K Hold
8,800
– – 0.04% 284
2020
Q2 		$278K Buy
+8,800
New +$277K 0.04% 369

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Quadrant's RVMD Position: Q1 2022 in Review

First Quadrant sold out of Revolution Medicines (RVMD) in Q1 2022, closing a stake of 10,700 shares — an estimated $269K sold.

First Quadrant first reported a position in RVMD in Q2 2020 and held it in 7 quarters. The position peaked at $404K in Q1 2021. 126 funds tracked by Wall St. Rank hold RVMD as of Q1 2022.

  • First Quadrant reported no remaining Revolution Medicines position as of Q1 2022 after selling out during the quarter.
  • First Quadrant sold 10,700 Revolution Medicines shares in Q1 2022, an estimated $269K.
  • First Quadrant first reported a position in Revolution Medicines in Q2 2020 and held it in 7 quarters.
  • First Quadrant's Revolution Medicines position peaked at $404K in Q1 2021.
  • 126 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.